journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Gastroenterology

journal
https://www.readbyqxmd.com/read/27803744/endoscopic-characteristics-and-usefulness-of-endoscopic-dilatation-of-anastomotic-stricture-following-pancreaticojejunostomy-case-series-and-a-review-of-the-literature
#1
REVIEW
Akihiko Kida, Yukihiro Shirota, Yuji Houdo, Tokio Wakabayashi
The incidence of pancreatitis induced by anastomotic stricture following pancreaticodigestive tract anastomosis as a late-onset adverse event has been reported to be 3% or lower, but some cases repeatedly relapse and are difficult to treat. Endoscopic identification and treatment of the anastomotic site are considered to be difficult, and only a small number of cases have been reported. We present three cases with recurrent pancreatitis induced by anastomotic stricture following pancreaticojejunostomy applied after pancreaticoduodenectomy...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803743/hepatocellular-adenoma-when-and-how-to-treat-update-of-current-evidence
#2
REVIEW
Maarten G Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A De Man, Adriaan Moelker, Jan N IJzermans
Hepatocellular adenoma (HCA) is a rare, benign liver tumor. Discovery of this tumor is usually as an incidental finding, correlated with the use of oral contraceptives, or pregnancy. Treatment options have focused on conservative management for the straightforward, smaller lesions (<5 cm), with resection preferred for larger lesions (>5 cm) that pose a greater risk of hemorrhage or malignant progression. In recent years, a new molecular subclassification of HCA has been proposed, associated with characteristic morphological features and loss or increased expression of immunohistochemical markers...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803742/direct-acting-antivirals-for-the-treatment-of-chronic-hepatitis-c-in-patients-with-chronic-kidney-disease
#3
REVIEW
Anita Kohli, Ali Alshati, Fawaz Georgie, Richard Manch, Robert G Gish
All-oral, direct-acting antivirals (DAAs) have significantly improved the efficacy and safety of chronic hepatitis C (CHC) treatment but their effectiveness and safety among patients with chronic kidney disease (CKD) remains poorly understood. Our aim was to assess the efficacy and safety of DAAs for treatment of CKD patients. The National Library of Medicine through PubMed was searched for studies evaluating the efficacy of DAAs for the treatment of patients with CKD stages 4 or 5, as defined by the Kidney Disease Outcomes Quality Initiative guidelines [i...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803741/the-biological-complexity-of-colorectal-cancer-insights-into-biomarkers-for-early-detection-and-personalized-care
#4
REVIEW
Marina De Rosa, Daniela Rega, Valeria Costabile, Francesca Duraturo, Antonello Niglio, Paola Izzo, Ugo Pace, Paolo Delrio
Colorectal cancer has been ranked the third and second most prevalent of all cancers in men and women, respectively, and it represents the fourth most common cause of cancer deaths. In 2012, there were 1.4 million estimated cases of colorectal cancer worldwide, and 700,000 estimated deaths, which implies significant impact on public health, especially in economically-developed countries. In recent years, there has been an increase in the number of tumors, although this has been accompanied by decreased mortality, due to more appropriate and available information, earlier diagnosis, and improvements in treatment...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803740/antagonizing-programmed-death-1-and-programmed-death-ligand-1-as-a-therapeutic-approach-for-gastric-cancer
#5
REVIEW
Xiaojun Liu, Zhongxia Yang, Olivier Latchoumanin, Liang Qiao
Malignant tumor cells are equipped with mechanisms that can help them escape the surveillance by host immune system. Immune checkpoint molecules can transduce coinhibitory signals to immunocompetent cells and exert immunosuppressive roles in antitumor immunity. Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are the two important checkpoint molecules with great potential in targeted cancer therapy. Several antibodies targeting PD-1 and PD-L1 have been approved for clinical use. In this review, we focus on the recent development of targeting PD-1 and PD-L1 in gastric cancer (GC) therapy...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803739/vonoprazan-based-therapy-for-helicobacter-pylori-eradication-experience-and-clinical-evidence
#6
REVIEW
Yuko Akazawa, Daisuke Fukuda, Yutaka Fukuda
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803738/helicobacter-pylori-and-gastric-acid-an-intimate-and-reciprocal-relationship
#7
REVIEW
Helge L Waldum, Per M Kleveland, Øystein F Sørdal
Helicobacter pylori (Hp) is the main cause of gastritis, peptic ulcer disease and gastric cancer. There are still unanswered questions related to the interaction between Hp and man, like what determines the susceptibility for the initial infection and the mechanisms for the carcinogenic effect. The initial infection seems to require a temporal gastric hypoacidity. For Hp to survive in the gastric mucous layer, some acidity is necessary. Hp itself is probably not directly carcinogenic. Only when inducing oxyntic mucosal inflammation and atrophy with hypoacidity, Hp predisposes for gastric cancer...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803737/impact-of-ornithine-phenylacetate-ocr-002-in-lowering-plasma-ammonia-after-upper-gastrointestinal-bleeding-in-cirrhotic-patients
#8
Meritxell Ventura-Cots, Mar Concepción, José Antonio Arranz, Macarena Simón-Talero, Maria Torrens, Albert Blanco-Grau, Inma Fuentes, Pilar Suñé, Edilmar Alvarado-Tapias, Cristina Gely, Eva Roman, Beatriz Mínguez, German Soriano, Joan Genescà, Juan Córdoba
BACKGROUND: Ornithine phenylacetate (OP) has been proven effective in lowering ammonia plasma levels in animals, and to be well tolerated in cirrhotic patients. A trial to assess OP efficacy in lowering plasma ammonia levels versus placebo in cirrhotic patients after an upper gastrointestinal bleeding was performed. The primary outcome was a decrease in venous plasma ammonia at 24 hours. METHODS: A total of 38 consecutive cirrhotic patients were enrolled within 24 hours of an upper gastrointestinal bleed...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803736/the-location-of-obstruction-predicts-stent-occlusion-in-malignant-gastric-outlet-obstruction
#9
Douglas Grunwald, Jonah Cohen, Anthony Bartley, Jennifer Sheridan, Ram Chuttani, Mandeep S Sawhney, Douglas K Pleskow, Tyler M Berzin, Meir Mizrahi
BACKGROUND: Gastric outlet obstruction (GOO) can occur with locally invasive or metastatic cancer involving the upper gastrointestinal tract at the pylorus or the duodenum. Endoscopic management with self-expanding metal stents (SEMSs) is often the preferred palliative approach. Stent occlusion is a common reason for failure and reintervention. We set out to determine whether the location of the malignant obstruction is associated with the angulation of the stent and can predict stent occlusion...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803735/prediagnosis-aspirin-use-and-outcomes-in-a-prospective-cohort-of-esophageal-cancer-patients
#10
James L Araujo, Nasser K Altorki, Joshua R Sonett, Adriana Rodriguez, Kivilcim Sungur-Stasik, Cathy F Spinelli, Alfred I Neugut, Julian A Abrams
BACKGROUND: Esophageal cancer remains associated with poor outcomes, yet little is known regarding factors that influence survival. Aspirin use prior to cancer diagnosis may influence outcomes. We aimed to assess the effects of prediagnosis aspirin use in patients with esophageal cancer. METHODS: We conducted a prospective cohort study of newly-diagnosed esophageal cancer patients at two tertiary care centers. We assessed history of prediagnosis aspirin use, and prospectively followed patients and assessed mortality, cause of death, and development of metastases...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803734/usefulness-of-spectral-computed-tomography-for-evaluation-of-intestinal-activity-and-severity-in-ileocolonic-crohn-s-disease
#11
Jiang Chen Peng, Qi Feng, Jiong Zhu, Jun Shen, Yu Qi Qiao, Jian Rong Xu, Zhi Hua Ran
BACKGROUND: Assessment of intestinal activity and severity of Crohn's disease (CD) is crucial to guide treatment. In this study, we aimed to investigate the accuracy of spectral computed tomography (CT) in this assessment and make a comparison with conventional CT. METHODS: A total of 50 patients with ileocolonic CD underwent spectral CT scanning. Conventional CT and spectral CT images were reconstructed. Endoscopic lesions were classified as absent, mild lesions and severe lesions...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803733/detection-of-anti-infliximab-antibodies-is-impacted-by-antibody-titer-infliximab-level-and-igg4-antibodies-a-systematic-comparison-of-three-different-assays
#12
Joana Afonso, Susana Lopes, Raquel Gonçalves, Paulo Caldeira, Paula Lago, Helena Tavares de Sousa, Jaime Ramos, Ana Rita Gonçalves, Paula Ministro, Isadora Rosa, Ana Isabel Vieira, Rosa Coelho, Patrícia Tavares, João Soares, Ana Lúcia Sousa, Diana Carvalho, Paula Sousa, João Pereira da Silva, Tânia Meira, Filipa Silva Ferreira, Cláudia Camila Dias, Yehuda Chowers, Shomron Ben-Horin, Fernando Magro
BACKGROUND: There is scant information on the accuracy of different assays used to measure anti-infliximab antibodies (ADAs), especially in the presence of detectable infliximab (IFX). We thus aimed to evaluate and compare three different assays for the detection of IFX and ADAs and to clarify the impact of the presence of circulating IFX on the accuracy of the ADA assays. METHODS: Blood samples from 79 ulcerative colitis (UC) patients treated with infliximab were assessed for IFX levels and ADAs using three different assays: an in-house assay and two commercial kits, Immundiagnostik and Theradiag...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803732/bioavailability-safety-and-pharmacodynamics-of-delayed-release-dexlansoprazole-administered-as-two-30-mg-orally-disintegrating-tablets-or-one-60-mg-capsule
#13
Michael Kukulka, Sai Nudurupati, Maria Claudia Perez
BACKGROUND: Dual delayed-release dexlansoprazole is approved for use in adults as a 30 mg orally disintegrating tablet (ODT) or as 30 mg and 60 mg capsules. The pharmacokinetics, pharmacodynamics, and safety profile of two dexlansoprazole 30 mg ODTs were compared with one dexlansoprazole 60 mg capsule in this randomized, phase I, open-label, single-center, multiple-dose, two-period crossover study. METHODS: Participants were randomized in one of two treatment sequences, each comprised two 5-day treatment periods during which two dexlansoprazole 30 mg ODTs or one 60 mg capsule was administered once daily...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27803731/pharmacokinetics-and-pharmacodynamics-of-an-orally-disintegrating-tablet-formulation-of-dexlansoprazole
#14
Michael Kukulka, Sai Nudurupati, Maria Claudia Perez
BACKGROUND: The pharmacokinetics and pharmacodynamics of a novel orally disintegrating tablet (ODT) formulation of delayed-release dexlansoprazole 30 mg was evaluated versus the dexlansoprazole 30 mg capsule in this phase I, open-label, multiple-dose, randomized, two-period crossover study. METHODS: Healthy adults received daily doses of 30 mg dexlansoprazole ODT or 30 mg dexlansoprazole delayed-release capsule for 5 days during two treatment periods, separated by a 7-day washout interval...
November 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27582889/the-mucosal-microbiota-in-a-young-child-with-severe-non-helicobacter-gastritis
#15
Geoffrey A Preidis, Ruth Ann Luna, Emily B Hollister, Deborah Schady, Chunxu Gao, Milton J Finegold, James Versalovic, Robert J Shulman
No abstract text is available yet for this article.
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27582888/safety-and-efficacy-of-vonoprazan-based-triple-therapy-against-helicobacter-pylori-infection-a-single-center-experience-with-1118-patients
#16
Daisuke Fukuda, Yuko Akazawa, Fuminao Takeshima, Kazuhiko Nakao, Yutaka Fukuda
No abstract text is available yet for this article.
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27582887/the-role-of-naloxegol-in-the-management-of-opioid-induced-bowel-dysfunction
#17
REVIEW
Wojciech Leppert, Jaroslaw Woron
Opioid-induced constipation (OIC) and other gastrointestinal (GI) symptoms of opioid-induced bowel dysfunction (OIBD) significantly deteriorate patients' quality of life and may lead to noncompliance with opioid schedule and undertreatment of pain. Although traditional oral laxatives are the first-line treatment of OIC, they do not address OIBD pathophysiology, and display numerous adverse effects. OIC treatment includes prokinetics (lubiprostone), opioid switch, and changing route of opioid administration...
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27582886/experience-with-biosimilar-infliximab-ct-p13-in-paediatric-patients-with-inflammatory-bowel-diseases
#18
REVIEW
Joanna Sieczkowska, Dorota Jarzębicka, Monika Meglicka, Grzegorz Oracz, Jaroslaw Kierkus
Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression of the disease, probably also decreasing morbidity and hospitalization rates, and improving patients' comfort. When the patent on infliximab started to expire, the first biosimilar of a monoclonal antibody was introduced onto the pharmacological market...
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27582885/placement-of-a-6-mm-fully-covered-metal-stent-for-main-pancreatic-head-duct-stricture-due-to-chronic-pancreatitis-a-pilot-study-with-video
#19
Takeshi Ogura, Saori Onda, Wataru Takagi, Masayuki Kitano, Tastsushi Sano, Atsushi Okuda, Akira Miyano, Daisuke Masuda, Toshihisa Takeuchi, Shinya Fukunishi, Kazuhide Higuchi
BACKGROUND: Temporary stent placement is widely performed for pancreatic duct stenosis due to chronic pancreatitis. A fully covered self-expandable metal stent (FCSEMS) has a larger diameter, and therefore longer stent patency, and the effect of expansion of the main pancreatic duct stricture may be obtained. However, if stent migration upstream occurs, stent removal is extremely difficult. In addition, because of the diameter gap between the FCSEMS and the main pancreatic duct, stent-induced ductal change may occur...
September 2016: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/27582884/closure-of-gastrointestinal-defects-with-ovesco-clip-long-term-results-and-clinical-implications
#20
Gianfranco Donatelli, Fabrizio Cereatti, Parag Dhumane, Bertrand Marie Vergeau, Thierry Tuszynski, Christian Marie, Jean-Loup Dumont, Bruno Meduri
BACKGROUND: The Over-The-Scope Clip (OTSC®, Ovesco Endoscopy GmbH, Tübingen, Germany) is an innovative clipping device that provides a strong tissue grasp and compression without provoking ischemia or laceration. In this retrospective study we evaluated immediate and long-term success rates of OTSC deployment in various pathologies of the gastrointestinal (GI) tract. METHODS: A total of 45 patients (35 female, 10 male) with an average age of 56 years old (range, 24-90 years) were treated with an OTSC for GI defects resulting from a diagnostic or interventional endoscopic procedure (acute setting group) or for fistula following abdominal surgery (chronic setting group)...
September 2016: Therapeutic Advances in Gastroenterology
journal
journal
42067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"